High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Novo Nordisk Powers Denmark’s Fastest Growth in Four Years

A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly ...
STAT

Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results

Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help ...

Novo Nordisk: Potential Winner With Value Trap Risks

Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...

Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly?

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...
Fierce Biotech

Pfizer finalizes Metsera buy after contentious bidding war with Novo Nordisk

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Novo Nordisk: A Rare Second Chance

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite ...

‘Not desperate’: Novo Nordisk’s new boss defends strategy

Just one month into his job, Novo Nordisk’s new chief executive went to bed one night in September thinking he had secured a ...